Experience with Netakimab and a GLP-1 agonist in patients with psoriasis and metabolic syndrome
https://doi.org/10.33667/2078-5631-2026-3-28-34
Abstract
Understanding the pathogenetic relationship between psoriasis and obesity is crucial, as excess weight can reduce the effectiveness of medications, highlighting its clinical significance not only in the context of disease severity but also in relation to therapeutic outcomes, including with the use of genetically engineered biological therapies. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a class of drugs that act on incretin hormone pathways, normalizing metabolic disorders. Clinical trials have been published on the use of GLP-1 agonists in patients with psoriasis. In this context, studying the combined use of genetically engineered drugs and GLP-1 agonists in patients with psoriasis and associated metabolic syndrome is relevant.
Material and methods. Twelve patients with psoriasis and metabolic syndrome were observed. All patients were prescribed netakimab 120 mg and tirzepatide according to the package insert.
Results. The PASI index (PASI) scores were statistically significant (p<0.001) from pre-treatment to week 26, reaching PASI 90 and 100 in all patients, indicating a significant clinical response to therapy. In the study group, the median weight loss was 14 kg (95% CI: 12.00–15.00), with a minimum weight loss of 10 kg and a maximum of 15 kg. The average percentage weight loss was 13.02±1.23.
Conclusions. A comprehensive approach to treating patients with severe psoriasis and associated metabolic syndrome with significant excess body weight is the most appropriate strategy, as this category of patients is at risk of an insufficient response to genetically engineered drugs. This observational study demonstrated the high efficacy and safety of a genetically engineered IL-17A blocker (netakimab) and tirzepatide.
About the Authors
L. S. Kruglova
Central State Medical Academy of the Administrative Department of the President of the Russian Federation
Russian Federation
Russian Federation
Kruglova Larisa S., Dr Med Sci (habil.), professor, head of Dept of Dermatovenereology and Cosmetology, rector
Moscow
A. S. Bridan-Rostovskaya
Central State Medical Academy of the Administrative Department of the President of the Russian Federation
Russian Federation
Russian Federation
Bridan-Rostovskaya Anna S., postgraduate student at Dept of Dermatovenereology and Cosmetology
Moscow
E. A. Shatokhina
Central State Medical Academy of the Administrative Department of the President of the Russian Federation ; Medical Scientific and Educational Institute of the Lomonosov Moscow State University
Russian Federation
Russian Federation
Shatokhina Evgeniya A., Dr Med Sci (habil.), professor at Dept of Dermatovenereology and Cosmetology, professor at Dept of Multidisciplinary Clinical Training, leading researcher at Dept of Internal Medicine
Moscow
References
1. Snekvik I, Smith CH, Nilsen TIL, et al. Obesity, Waist Circumference, Weight Change, and Risk of Incident Psoriasis: Prospective Data from the HUNT Study. J Invest Dermatol. 2017; 137 (12): 2484–2490. DOI: 10.1016/j.jid.2017.07.822
2. Kumar S, Han J, Li T, Qureshi AA. Obesity, waist circumference, weight change and the risk of psoriasis in US women. J Eur Acad Dermatol Venereol. 2013; 27 (10): 1293–1298. https://doi.org/10.1111/jdv.12001
3. Yamazaki F. Psoriasis: Comorbidities. J Dermatol. 2021; 48 (6): 732–740. DOI: 10.1111/1346-8138.15840
4. Gao N, Kong M, Li X, et al. The Association Between Psoriasis and Risk of Cardiovascular Disease: A Mendelian Randomization Analysis. Front Immunol. 2022; 13: 918224. Published 2022 Jun 29. DOI: 10.3389/fimmu.2022.918224
5. Zhang L, Wang Y, Qiu L, Wu J. Psoriasis and cardiovascular disease risk in European and East Asian populations: evidence from meta-analysis and Mendelian randomization analysis. BMC Med. 2022; 20 (1): 421. Published 2022 Nov 1. DOI: 10.1186/s12916-022-02617-5
6. Wu JJ, Kavanaugh A, Lebwohl MG, et al. Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasis. J Eur Acad Dermatol Venereol. 2022; 36 (6): 797–806. DOI: 10.1111/jdv.18044
7. Wong Y, Nakamizo S, Tan KJ. et al. An Update on the Role of Adipose Tissues in Psoriasis. Front Immunol. 2019; 10: 1507. Published 2019 Jun 28. DOI: 10.3389/fimmu.2019.01507
8. Wang, H., Hou, S., Kang, X. et al. BMI matters: understanding the link between weight and severe psoriasis. Sci Rep 15, 11158 (2025). https://doi.org/10.1038/s41598-025-94505-0
9. Toussirot E, Gallais-Sérézal I, Aubin F. The cardiometabolic conditions of psoriatic disease. Front Immunol. 2022; 13: 970371. Published 2022 Sep 8. DOI: 10.3389/fimmu.2022.970371
10. Lubrano E, Scriffignano S, Azuaga AB, et al. Impact of Comorbidities on Disease Activity, Patient Global Assessment, and Function in Psoriatic Arthritis: A Cross-Sectional Study. Rheumatol Ther. 2020; 7 (4): 825–836. DOI: 10.1007/s40744-020-00229-0
11. Hjort G, Schwarz CW, Skov L, Loft N. Clinical Characteristics Associated With Response to Biologics in the Treatment of Psoriasis: A Meta-analysis. JAMA Dermatol.2024; 160 (8): 830–837. DOI: 10.1001/jamadermatol.2024.1677
12. Enos CW, Ramos VL, McLean RR, et al. Comorbid obesity and history of diabetes are independently associated with poorer treatment response to biologics at 6 months: a prospective analysis in Corrona Psoriasis Registry. J Am Acad Dermatol. 2022; 86 (1): 68–76. https://doi.org/10.1016/j.jaad.2021.06.883
13. Armstrong AW, Fitzgerald T, McLean RR, et al. The effectiveness of guselkumab by BMI category among patients with moderate-to-severe plaque psoriasis in the CorEvitas Psoriasis Registry. Adv Ther. 2023; 40 (5): 2493–2508. https://doi.org/10.1007/s12325-023-02467-4
14. Jang J, Park M, Kim HJ, Jung Y. Reprogramming immunity at the metabolic-epidermal interface in obesity-associated psoriasis. Cytokine Growth Factor Rev. Published online January 9, 2026. DOI: 10.1016/j.cytogfr.2026.01.003
15. Burshtein J, Armstrong A, Chow M, et al. The association between obesity and efficacy of psoriasis therapies: An expert consensus panel. J Am Acad Dermatol. 2025; 92 (4): 807–815. DOI: 10.1016/j.jaad.2024.12.016
16. Egeberg A, Sørensen JA, Gislason GH, et al. Incidence and prognosis of psoriasis and psoriatic arthritis in patients undergoing bariatric surgery. JAMA Surg. 2017;152(4): 344–349. https://doi.org/10.1001/jamasurg.2016.4610
17. Laskowski, Marta et al. “Impact of Bariatric Surgery on Moderate to Severe Psoriasis: A Retrospective Nationwide Registry Study.” Acta dermato-venereologica vol. 101,6 adv00487. 30 Jun. 2021, DOI: 10.2340/00015555–3825
18. Wang JY, Wang QW, Yang XY, et al. GLP-1 receptor agonists for the treatment of obesity: Role as a promising approach. Front Endocrinol (Lausanne). 2023; 14: 1085799. Published 2023 Feb 1. DOI: 10.3389/fendo.2023.1085799
19. Nauck MA, Meier JJ. Incretin hormones: Their role in health and disease. Diabetes Obes Metab. 2018; 20 Suppl 1: 5–21. DOI: 10.1111/dom.13129
20. Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. 2018; 27 (4): 740–756. DOI: 10.1016/j.cmet.2018.03.001
21. Nauck M. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diabetes Obes Metab. 2016; 18 (3): 203–216. DOI: 10.1111/dom.12591
22. Popoviciu, Mihaela-Simona et al. “Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials.” International journal of molecular sciences vol. 24, 1310449. 21 Jun. 2023, DOI: 10.3390/ijms241310449
23. Xie Z, Zheng G, Liang Z, et al. Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials. Metabolism. 2024; 161: 156038. DOI: 10.1016/j.metabol.2024.156038
24. Paschou IA, Sali E, Paschou SA, et al. The effects of GLP-1RA on inflammatory skin diseases: A comprehensive review. J Eur Acad Dermatol Venereol. 2025; 39 (12): 2047–2055. DOI: 10.1111/jdv.20694
25. Bendotti G, Montefusco L, Lunati ME, et al. The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists. Pharmacol Res. 2022; 182: 106320. DOI: 10.1016/j.phrs.2022.106320
26. Brennan PJ, Brigl M, Brenner MB. Invariant natural killer T cells: an innate activation scheme linked to diverse effector functions. Nat Rev Immunol. 2013; 13 (2): 101–117. DOI: 10.1038/nri3369
27. Lee SW, Park HJ, Van Kaer L, Hong S. Role of CD1d and iNKT cells in regulating intestinal inflammation. Front Immunol. 2024; 14: 1343718. Published 2024 Jan 11. DOI: 10.3389/fimmu.2023.1343718
28. Hogan, A., Tobin, A., Ahern, T. et al. (2011) Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis. Diabetologia 54: 2745–2754.
29. Wen AY, Sakamoto KM, Miller LS. The role of the transcription factor CREB in immune function. J Immunol. 2010; 185 (11): 6413–6419. DOI: 10.4049/jimmunol.1001829
30. Drucker DJ, Rosen CF. Glucagon-like peptide-1 (GLP-1) receptor agonists, obesity and psoriasis: diabetes meets dermatology. Diabetologia. 2011; 54 (11): 2741–2744. DOI: 10.1007/s00125–011–2297-z
31. Cai Y, Shen X, Ding C, et al. Pivotal role of dermal IL-17- producing γδ T cells in skin inflammation. Immunity. 2011; 35 (4): 596–610.
32. Faurschou A, Pedersen J, Gyldenløve M, et al. Increased expression of glucagon-like peptide-1 receptors in psoriasis plaques. Exp Dermatol. 2013; 22 (2): 150–152. DOI: 10.1111/exd.12081
33. Chen P, Lin L, Xu X, et al. Liraglutide improved inflammation via mediating IL-23/Th-17 pathway in obese diabetic mice with psoriasiform skin. J Dermatolog Treat. 2021; 32 (7): 745–751. DOI: 10.1080/09546634.2019.1708853
34. Lin L, Xu X, Yu Y, et al. Glucagon-like peptide-1 receptor agonist liraglutide therapy for psoriasis patients with type 2 diabetes: a randomized-controlled trial. J Dermatolog Treat. 2022; 33 (3): 1428–1434. DOI: 10.1080/09546634.2020.1826392
35. Deng S, Chen Z, Shi Y. Roles of glucagon-like peptide 1 receptor agonists in immune cell biology and autoimmune/autoinflammatory diseases. Cell Biosci. 2025; 15 (1): 137. Published 2025 Oct 10. DOI: 10.1186/s13578-025-01486-8
36. Yang J, Wang Z, Zhang X. GLP-1 receptor agonist impairs keratinocytes inflammatory signals by activating AMPK. Exp Mol Pathol. 2019; 107: 124–128. https://doi.org/10.1016/j.yexmp.2019.01.014
37. Marx N, Burgmaier M, Heinz P, et al. Glucagon-like peptide-1(1–37) inhibits chemokine-induced migration of human CD4-positive lymphocytes. Cell Mol Life Sci. 2010; 67 (20): 3549–3555. DOI: 10.1007/s00018-010-0396-5
38. Buonanno S, Gaggiano C, Terribili R, et al. The potential role of GLP-1 receptor agonists in the management of psoriatic disease: a scoping review. Inflamm Res. 2025; 74 (1): 167. Published 2025 Nov 21. DOI: 10.1007/s00011-025-02140-2
39. Nicolau J, Nadal A, Sanchís P, et al. Effects of liraglutide among patients living with psoriasis and obesity. Med Clin (Barc). 2023; 161 (7): 293–6.
40. Petković-Dabić J, Binić I, Carić B, et al. Effects of semaglutide treatment on psoriatic lesions in obese patients with type 2 diabetes mellitus: an open-label, randomized clinical trial. Biomolecules. 2025; 15: 46
41. Faurschou A, Gyldenløve M, Rohde U, et al. Lack of effect of the glucagon-like peptide-1 receptor agonist liraglutide on psoriasis in glucose-tolerant patients-a randomized placebo-controlled trial. J Eur Acad Dermatol Venereol. 2015; 29 (3): 555–559
42. Chang G, Chen B, Zhang L. Efficacy of GLP-1rA, liraglutide, in plaque psoriasis treatment with type 2 diabetes: a systematic review and meta- analysis of prospective cohort and before-after studies. J Dermatol Treat. 2022; 33: 1299–305
43. Ku SC, Chang HC. Efficacy of glucagon-like peptide-1 receptor agonists for psoriasis: An updated systematic review and meta-analysis. J Dtsch Dermatol Ges. 2024;22(8):1148–1152. DOI: 10.1111/ddg.15431
44. Amanda Paredes-Barbeito, Madison Downs, Madeline Tchack, Noah Musolff, Babar Rao, Psoriasis and glucagon-like peptide-1 agonists: A scoping review, JAAD Reviews, Volume 6, 2025, Pages 39–40.
45. Pantazopoulos D, Gouveri E, Papi M, et al. GLP-1 Receptor Agonists, DPP-4 Inhibitors and the Skin-Diabetes Meets Dermatology: A Brief Narrative Review. Adv Ther. 2025; 42 (8):3621-3633. DOI: 10.1007/s12325–025–03257-w
46. Gonzalez-Rellan MJ, Drucker DJ. The expanding benefits of GLP-1 medicines. Cell Rep Med. 2025; 6 (7): 102214. DOI: 10.1016/j.xcrm.2025.102214
Review
For citations:
Kruglova L.S., Bridan-Rostovskaya A.S., Shatokhina E.A. Experience with Netakimab and a GLP-1 agonist in patients with psoriasis and metabolic syndrome. Medical alphabet. 2026;(3):28-34. (In Russ.) https://doi.org/10.33667/2078-5631-2026-3-28-34
Views:
108
JATS XML
Email this article 